NEWSROOM
PRESS RELEASES
March 28, 2022
Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis
SAN DIEGO, March 28, 2022 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the dosing of the first patient in its Phase 2b trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of palmoplantar pustulosis (PPP), a rare inflammatory skin disorder. read more →
January 14, 2022
Aristea Therapeutics Announces Key Leadership Appointments to Advance its Clinical Pipeline
SAN DIEGO, Jan. 13, 2022 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat rare serious inflammatory diseases, today announced the appointment of Ciara Kennedy as Aristea Therapeutics' Chair of the Board of Directors and Fabio Magrini as Executive Medical Director. read more →
IN THE NEWS
Two Disabled Dudes Podcast
May 15, 2022Doing the Right Thing with James Mackay, CEO Aristea Tx
James Mackay, PhD, Founder, President and Chief Executive Officer of Aristea Therapeutics, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. James joins The Dudes to discuss his experience and how he is contributing to the biotech leadership community. read more →
BioSpace
April 4, 2022Clinical Catch-Up: Adagio to Seek COVID-19 EUA, CytoDyn’s Bad Week
It was a particularly busy week for clinical trial announcements. read more →
EVENTS
2nd Annual Symposium for Inflammatory Skin Diseases Virtual
June 10, 2022Aristea will be sponsoring and exhibiting at the 2nd Annual Symposium for Inflammatory Skin Diseases Virtual. read more →